BioCentury | Jan 5, 2017
Clinical News

ATI-50001: Ph I started

...trial to evaluate oral ATI-50001 in 12 healthy volunteers. Aclaris has exclusive, worldwide rights to ATI-50001...
...Inc. (NASDAQ:ACRS), Malvern, Pa. Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), South San Francisco, Calif. Product: ATI-50001 (formerly A-201...
...Indication: Treat alopecia areata Endpoint: Safety, bioavailability and pharmacokinetics Status: Phase I started Milestone: NA Julian Zhu ATI-50001 Aclaris...
BioCentury | May 28, 2016
Financial News

Aclaris raises $20M in private placement

...submission slated for 4Q16. The company also intends to submit an IND next half for ATI-50001...
Items per page:
1 - 2 of 2